Clinical results using biochemotherapy as a standard of care in advanced melanoma Journal Article


Authors: Chapman, P. B.; Panageas, K. S.; Williams, L.; Wolchok, J. D.; Livingston, P. O.; Quinn, C.; Hwu, W. J.
Article Title: Clinical results using biochemotherapy as a standard of care in advanced melanoma
Abstract: Phase II studies of biochemotherapy in metastatic melanoma patients have reported response rates of 47-63%. Even though these were highly selected patients, we were intrigued by these promising response rates and began using this regimen as standard care in advanced melanoma patients. We report the results of the first 65 patients with AJCC stage IV melanoma (n = 57) or unresectable stage III (n = 8) melanoma treated with concurrent biochemotherapy at Memorial Hospital. Treatment was repeated every 3 weeks and patients were assessed for antitumour effects after every other cycle. The overall response rate among the 63 patients evaluable for response was 29% (three complete responses, 15 partial responses). The median duration of responses was 3.7 months. The response rate among previously treated and previously untreated patients was 6% and 38%, respectively. The estimated median survival for all patients was 8.5 months; the median survival for previously untreated patients was 9.2 months. Tumour response did not correlate with survival. Our experience, which is a retrospective evaluation, does not provide support for the routine use of biochemotherapy as standard treatment. The Iow response rate among previously treated patients indicates that biochemotherapy is not useful as second-line therapy. © 2002 Lippincott Williams & Wilkins.
Keywords: survival; adolescent; adult; cancer chemotherapy; cancer survival; human tissue; treatment outcome; aged; middle aged; survival analysis; treatment failure; retrospective studies; major clinical study; mortality; neutropenia; salvage therapy; cisplatin; advanced cancer; drug efficacy; multimodality cancer therapy; combined modality therapy; antineoplastic agent; alpha2b interferon; dacarbazine; interleukin 2; melanoma; metastasis; erythropoietin; vomiting; antineoplastic combined chemotherapy protocols; lorazepam; granulocyte macrophage colony stimulating factor; pathology; retrospective study; vinblastine; cost effectiveness analysis; drug cost; economics; drug costs; hypotension; survival time; correlation analysis; neoplasm metastasis; remission; remission induction; granisetron; granulocyte colony stimulating factor; granulocyte colony-stimulating factor; cost-benefit analysis; cost benefit analysis; interleukin-2; middle age; interferon-α; biological response modifier; biological response modifiers; biochemotherapy; response rate; interferon alfa-2b; second-line therapy; life tables; humans; human; male; female; priority journal; article; life table; intedeukin-2
Journal Title: Melanoma Research
Volume: 12
Issue: 4
ISSN: 0960-8931
Publisher: Lippincott Williams & Wilkins  
Date Published: 2002-08-01
Start Page: 381
End Page: 387
Language: English
DOI: 10.1097/00008390-200208000-00011
PUBMED: 12170188
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Jedd D Wolchok
    669 Wolchok
  2. Wen-Jen Hwu
    28 Hwu
  3. Paul Chapman
    251 Chapman
  4. Katherine S Panageas
    331 Panageas
  5. Carolyn J Quinn
    5 Quinn